Vaccine developed to beat dengue fever faces clinical trial

Brazilian researchers are launching a clinical trial for a vaccine that could prevent dengue fever.

Researchers in Brazil are launching a clinical trial for a vaccine they believe can prevent dengue fever, a potentially fatal disease transmitted by mosquitoes.

“Researchers in NIAID’s Laboratory of Infectious Diseases spent many years developing and testing dengue vaccine candidates designed to elicit antibodies against all four dengue virus serotypes,” NIAID Director Dr. Anthony Fauci said. “Earlier clinical trials of this candidate conducted in the U.S. by NIAID showed that it could elicit a robust antibody and cellular immune response after just one dose. Because the impact of dengue fever in Brazil is especially large and the country has an excellent health infrastructure, it is an ideal location to test the vaccine candidate.” 

The new vaccine, TV003, was developed by scientists at the National Institute of Allergy and Infectious Diseases, which is a branch of the National Institutes for Health. Dengue fever affects many countries in tropic and subtropic regions. It is estimated that nearly 400 million infections of the fever occur every year, while nearly 500,000 are hospitalized, according to the World Health Organization. Brazil reported over 1.5 million cases in 2015.

The new trial will enroll nearly 17,000 healthy people between the ages of two and 59. Candidates will come from 13 cities.

Organizations in this story

National Institute of Allergy and Infectious Diseases (NIAID) 5601 Fishers Lane, MSC 9806 Bethesda, MD 20892-9806

Get notified the next time we write about National Institute of Allergy and Infectious Diseases (NIAID)!